Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3
Withdrawn
Conditions
Lymphoma
First Posted Date
2011-07-01
Last Posted Date
2015-01-21
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT01386398

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

First Posted Date
2011-06-27
Last Posted Date
2021-10-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
9
Registration Number
NCT01381692
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States

and more 8 locations

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2011-06-13
Last Posted Date
2024-10-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1645
Registration Number
NCT01371981
Locations
🇺🇸

AdventHealth Orlando, Orlando, Florida, United States

🇺🇸

Blank Children's Hospital, Des Moines, Iowa, United States

🇺🇸

Albany Medical Center, Albany, New York, United States

and more 217 locations

Treatment of Sickle Cell Anemia With Stem Cell Transplant

First Posted Date
2011-05-09
Last Posted Date
2016-11-29
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
2
Registration Number
NCT01350232
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Phase 2
Terminated
Conditions
Disorder of Transplanted Kidney
Interventions
Drug: Bortezomib
First Posted Date
2011-05-06
Last Posted Date
2015-10-28
Lead Sponsor
Mark Stegall
Target Recruit Count
4
Registration Number
NCT01349595
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

First Posted Date
2011-04-19
Last Posted Date
2020-12-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
9
Registration Number
NCT01337752
Locations
🇬🇧

Novartis Investigative Site, Southampton, United Kingdom

🇺🇸

University Chicago Hospital Dept. of Univ of Chicago (2), Chicago, Illinois, United States

🇺🇸

Medical Oncology Associates, PS, Spokane, Washington, United States

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

First Posted Date
2011-04-05
Last Posted Date
2016-02-12
Lead Sponsor
University of Pittsburgh
Registration Number
NCT01329289
Locations
🇺🇸

Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

First Posted Date
2011-04-04
Last Posted Date
2011-09-22
Lead Sponsor
Clinical Service, China
Target Recruit Count
20
Registration Number
NCT01328236
Locations
🇨🇳

Beijing Clinical Service Center, Beijing, Beijing, China

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

First Posted Date
2011-03-29
Last Posted Date
2016-04-15
Lead Sponsor
University Hospital Southampton NHS Foundation Trust
Target Recruit Count
1132
Registration Number
NCT01324596
Locations
🇬🇧

Ysbyty Gwynedd Hospital, Bangor, United Kingdom

🇬🇧

Doncaster Royal Infirmary, Doncaster, United Kingdom

🇬🇧

Queen Elizabeth Hospital, Gateshead, Gateshead, United Kingdom

and more 105 locations

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

First Posted Date
2011-03-28
Last Posted Date
2017-05-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
35
Registration Number
NCT01323920
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy